ALXO ALX ONCOLOGY HOLDINGS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1810182 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.4%
TTM EPS YoY56.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-94.4%
ROA-67.9%
ROIC (approx.)-99.6%
Asset turnover—
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.08x
Current ratio8.04x
Interest coverage-67.78x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $17.46M | $13.14M | $13.61M | $17.64M | $17.44M | $18.02M | $23.89M | $23.53M |
| SG&A expense | $5.48M | $5.13M | $5.36M | $5.38M | $5.09M | $5.45M | $7.93M | $7.08M |
| Operating income | -$22.95M | -$18.03M | -$18.97M | -$23.02M | -$22.53M | -$26.65M | -$31.82M | -$30.61M |
| Interest expense | $225,000 | $285,000 | $331,000 | $383,000 | $408,000 | $405,000 | $406,000 | $427,000 |
| Net income | -$21.83M | -$17.97M | -$17.93M | -$22.85M | -$22.14M | -$25.95M | -$30.75M | -$29.16M |
| EBITDA | -$22.85M | -$17.93M | -$18.82M | -$22.87M | -$22.33M | -$26.45M | -$31.61M | -$30.40M |
| EPS (basic) | -0.15 | -0.13 | -0.17 | — | -0.41 | -0.49 | -0.58 | — |
| EPS (diluted) | -0.15 | -0.13 | -0.17 | — | -0.41 | -0.49 | -0.58 | — |
| Weighted avg. shares (diluted) | 140.90M | 135.64M | 104.57M | — | 53.58M | 53.45M | 53.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $35.45M | $22.69M | $32.28M | $16.37M | $23.44M | $19.30M | $20.61M | $17.63M |
| Short-term investments | $111.75M | $115.54M | $108.04M | $28.42M | $37.18M | $60.01M | $77.22M | $110.19M |
| Current assets | $152.87M | $143.46M | $145.56M | $50.73M | $66.52M | $85.26M | $102.53M | $134.35M |
| PP&E, net | $149,000 | $166,000 | $1.05M | $1.20M | $1.35M | $1.50M | $2.70M | $2.90M |
| Total assets | $154.67M | $160.82M | $178.33M | $59.05M | $82.72M | $95.32M | $120.90M | $147.78M |
| Current liabilities | $19.02M | $14.78M | $20.18M | $24.55M | $27.72M | $18.85M | $18.74M | $18.50M |
| Short-term debt | $0 | $0 | $5.22M | $5.22M | $4.35M | $3.04M | $1.74M | $435,000 |
| Long-term debt | $9.74M | $9.71M | $3.29M | $4.53M | $5.76M | $7.00M | $8.23M | $9.47M |
| Total debt | $9.74M | $9.71M | $8.51M | $9.75M | $10.11M | $10.04M | $9.97M | $9.90M |
| Total liabilities | $28.82M | $24.63M | $26.98M | $33.06M | $37.92M | $30.91M | $32.60M | $34.16M |
| Shareholders' equity | $125.85M | $136.19M | $151.35M | $25.98M | $44.80M | $64.42M | $88.30M | $113.62M |
| Net debt | -$25.71M | -$12.98M | -$23.77M | -$6.62M | -$13.33M | -$9.26M | -$10.64M | -$7.73M |
| Shares outstanding | 142.63M | 138.22M | 138.22M | 54.39M | 53.58M | 53.51M | 53.38M | 53.05M |
| Cash flow statement | ||||||||
| Operating cash flow | -$14.74M | -$16.06M | -$18.65M | -$18.98M | -$17.09M | -$23.41M | -$24.66M | -$32.05M |
| Capital expenditure | $65,000 | $17,000 | $50,000 | $49,000 | $56,000 | $47,000 | $60,000 | $60,000 |
| Free cash flow | -$14.80M | -$16.07M | -$18.70M | -$19.03M | -$17.15M | -$23.45M | -$24.72M | -$32.11M |
| Investing cash flow | $19.24M | $6.52M | -$105.04M | $11.23M | $21.39M | $22.32M | $27.64M | $33.18M |
| Financing cash flow | $8.20M | $137,000 | $139.59M | $678,000 | -$159,000 | -$222,000 | $65,000 | $328,000 |
| Depreciation & amortization | $100,000 | $100,000 | $150,000 | $151,000 | $200,000 | $200,000 | $211,000 | $214,000 |
| Stock-based compensation | $2.89M | $2.68M | $2.51M | $2.71M | $2.52M | $2.14M | $5.22M | $5.86M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.